Sanofi and GlaxoSmithKline (GSK) have entered into a partnership to develop a COVID-19 vaccine that includes an adjuvant to boost the immune response.

Sanofi will contribute its S-protein COVID-19 antigen while GSK will provide its adjuvant technology.

The drugmakers plan to begin phase 1 clinical trials in the second half of 2020 and hope to have a vaccine available by the second half of 2021.